In Brief: Schmidt Sells OMB On Training Grants, But Weinberger Is The One To Convince

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Benno Schmidt, chairman of the President’s Cancer Panel, feels he made progress when he argued NCI’s case on research training grants and fellowships with Office of Management & Budget. In this instance, however, OMB will not have the last word. HEW Secretary Caspar Weinberger decided, when he headed OMB, to kill the NIH training pro­gram and wouldn’t change his mind after moving to HEW. Congress may have forced Weinberger to back down (See HEW budget story page 2) …. 

NCI Director Frank Rauscher says the most damaging blow to cancer research has been the Administration’s ceiling on posi­tions. NCI scientists are doing clerical work because OMB (or Wein­berger) won’t permit Rauscher to hire more people. Rauscher may put to use the authority he has to bypass HEW and take his case directly to the President, and Congress …. 

Another level of contract review may be superimposed over NIH procedures by HEW. Asst. Secretary for Health Charles Edwards is considering establishing review in his office for contracts over $1 million. Rauscher fears this would add 1-2 months to review time already requiring 5-7 months.

YOU MAY BE INTERESTED IN

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login